knowledge -WSS

knowledge

author：hotspot 2025-10-02 20:48:11 - browse：66

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Vaccine advisory panel ACIP left half staffed by HHS

hotspot

WSS

How digital tools helped lower hypertension in marginalized patients

Gilead might be held responsible for not developing a drug

Biogen Alzheimer’s drug launch off to slow start

Congenital heart disease patients face new threat of heart failure

Senators start work on Medicare physician payment reform

Robert F. Kennedy is pitching centrism on health, even on abortion

focus

knowledge

focus

The high cost of giving birth even with insurance

What PEPFAR has meant on the ground in Ukraine

Anesthesiologist group: stop taking Ozempic before surgery

Biden report: The neurospychology of memory and aging

Hollywood unions extend contract negotiations for actors

AI models in health care face new federal disclosure requirements

Sports medicine is finally prioritizing gender equality

Pfizer plans to depart BIO

Apple is now the first public company to be valued at $3 trillion

PhRMA lawsuit over Medicare drug price negotiation tossed

leisure time

Congenital heart disease patients face new threat of heart failure

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

BioAge raises $170M for combination therapy with Zepbound

Roche to buy Carmot Therapeutics, developer of obesity drugs

Medicare Advantage proposed rates disappoint insurers

explore

focus

hotspot

explore